Healthcare / Medical Instruments & SuppliesASX
$0.01
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-3.1M · quality 73.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4M
P/E
N/A
•EV/EBITDA
N/A
•ROE
215.6%
↑Gross Margin
77.5%
↑Debt/Equity
-1.62
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+21.8%
FCF CAGR
—
FCF margin
-83.5%
FCF / Net income
0.69x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.1M · net income $-3.7M · FCF $-2.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.1M | $3.1M | $2.9M | $2.2M | $1.7M |
| Net Income | $-3.7M | $-3.7M | $-3.4M | $-4.9M | $-4.2M |
| EBITDA | $-2.9M | $-2.9M | $-2.4M | $-4.3M | $-4.0M |
| EPS | — | — | -0.03 | -0.08 | -0.09 |
| Gross Margin | 77.5% | 77.5% | 84.0% | 73.8% | 75.2% |
| Operating Margin | -111.6% | -111.6% | -99.8% | -225.7% | -264.8% |
| Net Margin | -121.8% | -121.8% | -115.1% | -219.7% | -247.9% |
| Balance Sheet | |||||
| Debt/Equity | -1.62 | -1.62 | 4.35 | 2.76 | 0.04 |
| Current Ratio | 0.85 | 0.85 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.6M | $-2.6M | $-3.1M | $-3.7M | $-4.0M |
| Returns | |||||
| ROE | 215.6% | 215.6% | -1094.8% | -1126.2% | -199.1% |
| Valuation | |||||
| P/B | — | — | 12.89 | 92.14 | 44.35 |
| Growth & Yield | |||||
| Revenue Growth | 5.0% | 5.0% | 31.3% | 31.0% | — |
| EPS Growth | — | — | 64.4% | 6.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-60.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → n/d
Residual
-60.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.